足関節全置換：グローバル市場分析と予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Catalyst 14
3 Disease Overview 15
3.1 Anatomy and Physiology 15
3.2 Pathophysiology 16
3.2.1 Overview 16
3.2.2 Post-Traumatic Arthritis 17
3.2.3 Inflammatory Arthritis 18
3.2.4 Primary Osteoarthritis 18
3.2.5 Others 19
3.3 Clinical Presentation 19
3.3.1 Symptoms 19
3.3.2 Diagnosis 20
3.4 Clinical Outcomes 21
3.4.1 Overview 21
3.4.2 Conservative Treatments 21
3.4.3 Joint-Preserving Surgeries 22
3.4.4 Definitive Procedures 25
3.5 Epidemiology 29
3.5.1 Prevalence 29
3.5.2 Treatments 30
3.6 Economic Impact 31
3.6.1 Economic Impact in the US 32
3.6.2 Economic Impact in Europe 33
3.6.3 Economic Impact in Rest of the World 33
4 Competitive Assessment 34
4.1 Overview 34
4.2 Competitive Assessment 35
4.3 Two-Component Fixed-Bearing 36
4.3.1 Agility LP 36
4.3.2 Salto Talaris 38
4.3.3 INBONE II 40
4.3.4 TNK 43
4.3.5 Zimmer Trabecular Metal Total Ankle 44
4.4 Three-Component Mobile-Bearing 46
4.4.1 Scandinavian Total Ankle Replacement (STAR) 46
4.4.2 Mobility 48
4.4.3 Salto 50
4.4.4 HINTEGRA 52
4.4.5 BOX (Bologna-Oxford) 54
4.4.6 Zenith 56
4.4.7 CCI Evolution 58
5 Unmet Needs 60
5.1 Long-Term Follow-Up 61
5.2 Commitment to Medical Education 61
5.3 Advanced Biological Fixation 62
5.4 Minimal Bone Resection 64
5.4.1 Tibial Component 64
5.4.2 Talar Component 65
5.5 Mobile-Bearing versus Fixed-Bearing 65
5.6 Bespoke Instrumentation 67
5.7 Custom Prostheses 67
5.8 Revision Components 68
6 Pipeline Products 69
6.1 Overview 69
6.2 INBONE II Total Ankle with Calcaneal Stem Fixation 69
6.2.1 Overview 69
6.2.2 SWOT Analysis 70
6.3 Akilos Total Ankle System 71
6.3.1 Overview 71
6.3.2 SWOT Analysis 72
7 Industry Overview 73
7.1 Procedure Trends 73
7.1.1 US 73
7.1.2 Europe 74
7.1.3 Asia-Pacific 75
7.1.4 South America 76
7.2 Market Access 77
7.2.1 Regulatory Process 77
7.2.2 Adoption 79
7.3 Reimbursement Trends 81
7.3.1 US 81
7.3.2 Europe 83
7.3.3 Asia-Pacific 86
7.3.4 South America 87
7.4 Regulatory Issues/Recalls 87
7.4.1 No Custom Devices for DePuy’s Agility Total Ankle Prosthesis in the US 87
7.4.2 Medical Device Alert for Biomet’s Ankle Evolutive System (AES) used in the UK 88
7.5 Mergers & Acquisitions/Key Partnerships 88
8 Current and Future Players 90
8.1 Overview 90
8.2 Trends in Corporate Strategy 90
8.3 Company Profiles 91
8.3.1 Small Bone Innovation, Inc. 91
8.3.2 DePuy Synthes 93
8.3.3 Tornier N.V. 95
8.3.4 Wright Medical Group, Inc. 96
8.3.5 Integra LifeSciences 99
8.3.6 Zimmer Holdings, Inc. 100
8.3.7 Corin Group 103
8.3.8 KYOCERA Medical Corporation 104
8.3.9 MatOrtho 106
8.3.10 Implants International 107
8.3.11 Other Companies 108
9 Market Drivers, Opportunities, and Barriers 109
9.1 Market Drivers 109
9.1.1 Superiority to Ankle Fusion 109
9.1.2 Rising Prevalence 110
9.1.3 Expanded Insurance Coverage 111
9.1.4 Availability of Long-Term Data 112
9.1.5 Increased Patient Awareness 112
9.1.6 Expected Launch of CE-Marked Devices 113
9.2 Opportunities 113
9.2.1 Expanded Indications 113
9.2.2 Advanced Biological Fixation Approaches 114
9.2.3 Revision TAR 114
9.2.4 Demand for Custom Prostheses 115
9.2.5 Demand for a Comprehensive Foot and Ankle Product Portfolio 115
9.2.6 Emerging Markets 116
9.3 Market Barriers 116
9.3.1 Preoperative Patient Selection 116
9.3.2 Long Learning Curve 117
9.3.3 Complications 118
9.3.4 Cost 118
9.3.5 Reimbursement 119
9.3.6 Substitutes 119
10 Country Outlooks and Forecasts 120
10.1 Major Markets Overview 120
10.2 US 122
10.2.1 US Market Analysis 122
10.3 France 124
10.3.1 France Market Analysis 124
10.4 Germany 126
10.4.1 Germany Market Analysis 126
10.5 Italy 127
10.5.1 Italy Market Analysis 127
10.6 Spain 129
10.6.1 Spain Analysis 129
10.7 UK 130
10.7.1 UK Market Analysis 130
10.8 Japan 132
10.8.1 Japan Market Analysis 132
10.9 Brazil 134
10.9.1 Brazil Market Analysis 134
10.10 China 135
10.10.1 China Market Analysis 135
10.11 India 137
10.11.1 India Market Analysis 137
11 Appendix 139
11.1 Abbreviations 139
11.2 Bibliography 140
11.3 Methodology 147
11.3.1 Coverage 147
11.3.2 Secondary Research 147
11.3.3 Primary Research 148
11.3.4 Forecasting Methodology 149
11.4 Physicians and Specialists Included in this Study 150
11.5 Physician Survey 151
11.6 About the Authors 151
11.6.1 Analysts 151
11.6.2 Global Head of Healthcare 152
11.7 About MediPoint 152
11.8 About GlobalData 153
11.9 Contact Us 153
11.10 Disclaimer 153